Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC88 in advanced solid tumours
NCT05508334Phase 2Completed
- Sponsor
- RemeGen
- Start
- Jan 2023
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of misitatug blivedotin in solid tumor, sponsored by RemeGen. Started Jan 2023; status: completed.
02
Drugs
misitatug blivedotin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05508334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05508334.